TY - JOUR
T1 - SFE-AFCE-SFMN 2022 consensus on the management of thyroid nodules
T2 - Surgical treatment
AU - Menegaux, Fabrice
AU - Baud, Gregory
AU - Chereau, Nathalie
AU - Christou, Niki
AU - Deguelte, Sophie
AU - Frey, Samuel
AU - Guérin, Carole
AU - Marciniak, Camille
AU - Paladino, Nunzia Cinzia
AU - Brunaud, Laurent
AU - Caiazzo, Robert
AU - Donatini, Gianluca
AU - Gaujoux, Sebastien
AU - Goudet, Pierre
AU - Hartl, Dana
AU - Lifante, Jean Christophe
AU - Mathonnet, Muriel
AU - Mirallié, Eric
AU - Najah, Haythem
AU - Sebag, Frederic
AU - Trésallet, Christophe
AU - Pattou, Francois
N1 - Publisher Copyright:
© 2022
PY - 2022/12/1
Y1 - 2022/12/1
N2 - The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons, but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies: the French Society of Endocrinology (SFE), French-speaking Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This section deals with the surgical management of thyroid nodules.
AB - The SFE-AFCE-SFMN 2022 consensus deals with the management of thyroid nodules, a condition that is a frequent reason for consultation in endocrinology. In more than 90% of cases, patients are euthyroid, with benign non-progressive nodules that do not warrant specific treatment. The clinician's objective is to detect malignant thyroid nodules at risk of recurrence and death, toxic nodules responsible for hyperthyroidism or compressive nodules warranting treatment. The diagnosis and treatment of thyroid nodules requires close collaboration between endocrinologists, nuclear medicine physicians and surgeons, but also involves other specialists. Therefore, this consensus statement was established jointly by 3 societies: the French Society of Endocrinology (SFE), French-speaking Association of Endocrine Surgery (AFCE) and French Society of Nuclear Medicine (SFMN); the various working groups included experts from other specialties (pathologists, radiologists, pediatricians, biologists, etc.). This section deals with the surgical management of thyroid nodules.
KW - Approach
KW - Consensus
KW - Hematoma
KW - Hypocalcemia
KW - Loboisthmectomy
KW - Neck dissection
KW - Neuromonitoring
KW - Outpatient surgery
KW - Recurrent nerve palsy
KW - Surgery
KW - Thyroid nodule
KW - Total thyroidectomy
UR - http://www.scopus.com/inward/record.url?scp=85142799116&partnerID=8YFLogxK
U2 - 10.1016/j.ando.2022.10.012
DO - 10.1016/j.ando.2022.10.012
M3 - Article
C2 - 36309207
AN - SCOPUS:85142799116
SN - 0003-4266
VL - 83
SP - 415
EP - 422
JO - Annales d'Endocrinologie
JF - Annales d'Endocrinologie
IS - 6
ER -